Difference between revisions of "Bone sarcoma"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.'''" to "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.'''")
m (Text replacement - "http://www.esmo.org/" to "https://www.esmo.org/")
 
(51 intermediate revisions by 4 users not shown)
Line 1: Line 1:
−
'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''
+
<span id="BackToTop"></span>
−
 
+
<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
−
Is there a regimen missing from this list?  Would you like to share a different dosage/schedule or an additional reference for a regimen?  Have you noticed an error?  Do you have an idea that will help the site grow to better meet your needs and the needs of many others?  You are [[How_to_contribute|invited to contribute to the site]].
+
[[#top|Back to Top]]
−
 
+
</div>
 +
{{#lst:Editorial board transclusions|sarcoma}}
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
|-
 
|-
−
|<div style="background-color: #66FF66; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} regimens on this page</b></font></div>
+
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
−
<div style="background-color: #66CCFF; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} variants on this page</b></font></div>
+
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 
|}
 
|}
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
−
<big>Note: this page is a gathering place for the 10+ subtypes of bone sarcoma. Subtypes with substantial numbers of regimens will be moved to their own pages, with links preserved here.</big>
+
<big>Note: this page is for subtype-nonspecific bone sarcoma regimens, and some subtypes with very few subtype-specific regimens. Please see the [[:Category:Bone sarcomas|category page]] for links to other sarcoma types or use one of these links:
 +
*[[Ewing sarcoma]]
 +
*[[Giant-cell tumor of bone]]
 +
*[[Osteosarcoma]]
 +
</big>
 
=Guidelines=
 
=Guidelines=
−
==ESMO==
+
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
−
*[http://annonc.oxfordjournals.org/content/25/suppl_3/iii113.full.pdf+html Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.] [https://www.ncbi.nlm.nih.gov/pubmed/25210081 PubMed]
+
==[https://www.esmo.org/ ESMO]/EURACAN/GENTURIS/PaedCan==
 +
*'''2021:''' Strauss et al. [https://doi.org/10.1016/j.annonc.2021.08.1995 Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/34500044/ PubMed]
 +
**'''2018:''' Casali et al. [https://doi.org/10.1093/annonc/mdy310 Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/30285218/ PubMed]
 +
**'''2014:''' [https://doi.org/10.1093/annonc/mdu256 Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/25210081/ PubMed]
 +
**'''2012:''' [https://doi.org/10.1093/annonc/mds254 Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/22997441/ PubMed]
 +
**'''2010:''' Hogendoorn et al. [https://doi.org/10.1093/annonc/mdq223 Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/20555083/ PubMed]
 +
 
 
==NCCN==
 
==NCCN==
−
*[https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf NCCN Guidelines - Bone Cancer]
+
*[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1418 NCCN Guidelines - Bone Cancer]
 +
*'''2013:''' Biermann et al. [https://doi.org/10.6004/Jnccn.2013.0088 Bone cancer.] [https://pubmed.ncbi.nlm.nih.gov/23744868/ PubMed]
 +
*'''2010:''' Biermann et al. [https://doi.org/10.6004/Jnccn.2010.0051 Bone cancer.] [https://pubmed.ncbi.nlm.nih.gov/20581300/ PubMed]
 +
*'''2007:''' Biermann et al. [https://doi.org/10.6004/Jnccn.2007.0037 Bone cancer.] [https://pubmed.ncbi.nlm.nih.gov/17442233/ PubMed]
 +
*'''2005:''' Biermann et al. Bone cancer clinical practice guidelines. [https://pubmed.ncbi.nlm.nih.gov/19817025/ PubMed]
  
 
=Chondrosarcoma, all lines of therapy=
 
=Chondrosarcoma, all lines of therapy=
Line 21: Line 36:
 
*Dedifferentiated chondrosarcoma has been treated with [[Osteosarcoma|osteosarcoma regimens]]
 
*Dedifferentiated chondrosarcoma has been treated with [[Osteosarcoma|osteosarcoma regimens]]
  
−
=Ewing's sarcoma, all lines of therapy=
+
=Undifferentiated pleomorphic sarcoma (UPS) of bone, all lines of therapy=
−
*Please see the [[Ewing's sarcoma|dedicated Ewing's sarcoma page]].
+
*Undifferentiated pleomorphic sarcoma (UPS) of bone has been treated with [[Osteosarcoma|osteosarcoma regimens]]
−
 
 
−
=Giant-cell tumor of bone, all lines of therapy=
 
−
==Denosumab monotherapy {{#subobject:65e2b|Regimen=1}}==
 
−
{| class="wikitable" style="float:right; margin-left: 5px;"
 
−
|-
 
−
|[[#top|back to top]]
 
−
|}
 
−
 
 
−
===Regimen {{#subobject:f50a28|Variant=1}}===
 
−
{| border="1" style="text-align:center;" !align="left"
 
−
|'''Study'''
 
−
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
 
−
|-
 
−
|[http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70010-3/fulltext Thomas et. al 2010]
 
−
|style="background-color:#EEEE00"|Phase II
 
−
|-
 
−
|}
 
−
====Primary therapy====
 
−
*[[Denosumab (Xgeva)]] as follows:
 
−
**Cycle 1: 120 mg SC once per day on days 1, 8, 15
 
−
**Cycle 2 onwards: 120 mg SC once on day 1
 
−
 
 
−
====Supportive medications====
 
−
*Calcium 500 mg PO once per day
 
−
*Vitamin D 400 IU PO once per day
 
−
 
 
−
'''28-day cycles, given until complete tumor resection, progression of disease, or patient choice'''
 
−
 
 
−
===References===
 
−
# Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010 Mar;11(3):275-80. [http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70010-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20149736 PubMed]
 
−
 
 
−
=Malignant fibrous histiocytoma (MFH) of bone, all lines of therapy=
 
−
*Malignant fibrous histiocytoma (MFH) of bone has been treated with [[Osteosarcoma|osteosarcoma regimens]]
 
−
 
 
−
=Osteosarcoma, all lines of therapy=
 
−
*Please see the [[osteosarcoma|dedicated osteosarcoma page]].
 
  
 
[[Category:Bone sarcoma regimens]]
 
[[Category:Bone sarcoma regimens]]
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
−
[[Category:Soft tissue sarcomas]]
+
[[Category:Bone sarcomas]]

Latest revision as of 17:51, 23 June 2024

Back to Top

Section editor
Elizabethdavis2.jpg
 Elizabeth J. Davis, MD
Vanderbilt University
Nashville, TN, USA
0 regimens on this page
0 variants on this page


Note: this page is for subtype-nonspecific bone sarcoma regimens, and some subtypes with very few subtype-specific regimens. Please see the category page for links to other sarcoma types or use one of these links:

Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

ESMO/EURACAN/GENTURIS/PaedCan

NCCN

Chondrosarcoma, all lines of therapy

Undifferentiated pleomorphic sarcoma (UPS) of bone, all lines of therapy

Retrieved from "https://hemonc.org/w/index.php?title=Bone_sarcoma&oldid=86505"